Abstract: Objective To explore the expressions of serum myeloid cell trigger receptor 1 (TREM-1), soluble CD163 molecule (sCD163), and soluble B7-H3 (sB7-H3) test in patients with primary liver cancer and their association with the patients' prognosis. Methods The clinical data of 110 cases of primary liver cancer treated in Zhongxian People's Hospital of Chongqing were collected. They were divided into a poor prognosis group (death, N=45) and a good prognosis group (survival, N=65). The basic information and the levels of TREM-1, sCD163 and SB7-H3 of the two groups of patients were detected. The value of serum TREM-1, sCD163 and SB7-H3 in predicting the poor prognosis of HCC patients were analyzed by receiver operating curve (ROC) and multivariate logistic regression analyses. Results The proportion of tumor size ≥5 cm, liver cirrhosis, vascular invasion, and TREM-1, sCD163, and sB7-H3 levels were all higher in the poor prognosis group than those in the good prognosis group (P<0.05). Tumor size≥5 cm, with liver cirrhosis, with vascular invasion, TREM-1≥3.625 ng/mL, sCD163≥1.520 μg/mL, and sB7-H3≥425.670 pg/mL were the risk factors for poor prognosis in primary HCC patients (P<0.05). Conclusion TREM-1, sCD163, and sB7-H3 tests may have value in predicting the prognosis of primary liver cancer.

Key words: Myeloid cells trigger receptor 1, Soluble CD163 molecule, Soluble B7-H3, Primary liver cancer